Docality.com Logo
 
Dr. Subhashini  Yaturu  Md image

Dr. Subhashini Yaturu Md

Overton Brooks Va Medical Ctr
Shreveport LA 71101
318 246-6076
Medical School: Other - Unknown
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 11466R
NPI: 1649374786
Taxonomy Codes:
207RE0101X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

None Found

Publications

Metastases to the thyroid presenting as a metabolically inactive incidental thyroid nodule with stable size in 15 months. - Case reports in endocrinology
Though the thyroid gland has a rich vascular supply, incidence of metastatic disease from distant organs is rare. Here we present an unusual case of metastases to the thyroid with several interesting features. A 63-year-old male with history of adenocarcinoma of the right lobe lung (5 years prior to presentation), treated with surgery and chemotherapy, followed by new adenosquamous lung cancer in the left lobe of the lung (one year prior to presentation), treated surgically followed by adjuvant chemotherapy, was referred to Endocrinology section for evaluation of an incidental thyroid nodule on CT chest. Ultrasound (US) of the thyroid revealed a complex, predominantly hypoechoic lesion measuring 1.8 cm within the lower pole of the right thyroid lobe and a subcentimeter lesion in the left lobe of the thyroid. Review of prior CT chests showed that the lesion in the right lobe was stable for 15 months, with no evidence of a hypermetabolic lesion on PET scan. The subcentimeter lesion was not seen on prior CT scans. US guided fine needle aspiration (FNA) and pathology of the lobectomy of the thyroid confirmed adenosquamous carcinoma. Interesting features in this case are that the thyroid metastases occurred without any evidence of synchronous lesions elsewhere, the size was stable over 15 months, and the lesions were metabolically inactive.
Insulin therapies: Current and future trends at dawn. - World journal of diabetes
Insulin is a key player in the control of hyperglycemia for type 1 diabetes patients and selective individuals in patients of type 2 diabetes. Insulin delivery systems that are currently available for the administration of insulin include insulin syringes, insulin infusion pumps, jet injectors and pens. The traditional and most predictable method for the administration of insulin is by subcutaneous injections. The major drawback of current forms of insulin therapy is their invasive nature. To decrease the suffering, the use of supersonic injectors, infusion pumps, sharp needles and pens has been adopted. Such invasive and intensive techniques have spurred the search for alternative, more acceptable methods for administering insulin. Several non-invasive approaches for insulin delivery are being pursued. The newer methods explored include the artificial pancreas with closed-loop system, transdermal insulin, and buccal, oral and pulmonary routes. This review focuses on the new concepts that are being explored for use in future.
Vitamin d levels in subjects with prostate cancer compared to age-matched controls. - Prostate cancer
Prostate cancer (PCa) is the second most common cancer in men worldwide and the second leading cause of cancer deaths in men in the United States. Vitamin D is considered to have anticancer properties, currently thought to work mainly through its nuclear receptor or vitamin D receptor. In this retrospective study, we compared vitamin D levels in subjects with PCa with those of age-matched men without PCa. Study subjects included 479 in each group with a mean age of 73 and a mean creatinine of 1.05 and 1.15. Levels of 25 (OH) vitamin D were 28.4 ± 0.54 and 28.05 ± 0.62 in subjects with and without PCa. Levels of 1,25 (OH) vitamin D were 47.2 ± 6.8 and 47.1 ± 7.11 in subjects with and without PCa. In contrast to other studies, we did not find a significant difference in vitamin D levels. Among prostate cancer patients, vitamin D levels correlated positively with age (r = 0.12, P < 0.02), and were negatively associated with BMI (r = -0.13, P = 0.003), glucose (r = -0.12, P < 0.007), HbA1C (r = -0.16, P = 0.001), and PTH (r = -0.21; P < 0.0001). The data do not show the causal effect of vitamin D levels on PCa.
Prevalence of Decreased Vitamin D Levels is High among Veterans with Diabetes and/or CKD. - ISRN endocrinology
Objective. Vitamin D deficiency is associated with a variety of skeletal and extraskeletal problems. The aim of this study was to evaluate the prevalence of vitamin D deficiency among veterans in sunny Louisiana. Methods. Using the VA computerized patient record system, we searched for all 25 (OH) Vitamin D and 1, 25 (OH) vitamin D levels that were measured between 2007 and 2009. The information collected for each patient included age, body mass index, creatinine, history of diabetes and hypertension, and levels of vitamin D and PTH. We determined the number of individuals who were vitamin D insufficient and deficient. Results. Among 2990 studies evaluated, the mean concentration of 25 (OH) D was 22.5 ± 0.2 ng/mL, and that of 1, 25 (OH) vitamin D was 29.2 ± 0.4 ng/mL. Among them, only 695 subjects (23%) had normal values, while 889 (30%) had insufficiency, and 1405 (47%) had deficiency. Subjects with diabetes (1041) had significantly (P < 0.0001) lower levels (21 and 25 ng/mL) of both 25 (OH) and 1,25 (OH) vitamin D compared to subjects without diabetes (23 and 32 ng/mL). Similarly, subjects with chronic kidney disease (1128) had much lower vitamin D levels than subjects without CKD. Among subjects with diabetes, those with chronic kidney disease (512) had much lower levels of both 25 (OH) and 1,25 (OH) vitamin D than with those with normal creatinine levels. Conclusions. We conclude that vitamin D insufficiency and deficiency is highly prevalent in veterans, more so among subjects with diabetes and/or CKD.
Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer. - Prostate cancer
Prostate cancer is one of the most common malignancies in men. Charles Huggins and Clarence V. Hodges reported the androgen dependence of prostate cancer in 1941. That led to the utilization of androgen deprivation therapy as an important therapeutic modality to treat prostate cancer. Androgen deprivation therapy has additional systemic effects that include sexual dysfunction, psychological changes and more important are the metabolic changes. Metabolic changes in particular include insulin resistance, increase fat mass and low-density lipoprotein cholesterol, and induce type 2 diabetes. In this review we will focus on the cardiovascular risk associated with androgen deprivation therapy that includes the mechanisms involved.
Diabetes and skeletal health. - Journal of diabetes
Osteoporosis and diabetes affect a large proportion of the elderly population. The prevalence of diabetes and osteoporosis is increasing. Compared with individuals without diabetes, both men and women with diabetes have a higher risk of fractures, particularly at the hip, with consequent significant morbidity and mortality. Type 1 diabetes is associated with decreased bone mass and although bone mass data for Type 2 diabetes may or may not be decreased, there is evidence of altered bone quality in diabetes. The mechanisms involved include effects of insulin, insulin-like growth factor 1, cytokines, advanced glycation end products, and altered calcium homeostasis. In addition, a drug-induced increase in the incidence of fractures has been noted with the use of thiazolidinediones (TZDs). TZDs improve insulin sensitivity and have multitude other beneficial effects. Osteoblasts and adipocytes are derived from a common multipotential mesenchymal stem cell progenitor, with activation of peroxisome proliferator-activated receptor γ2 by both currently available TZDs (i.e. rosiglitazone and pioglitazone) stimulating adipogenesis and inhibiting osteoblastogenesis. The use of both rosiglitazone and pioglitazone is associated with an increased fracture risk, with changes in bone turnover markers and decreased bone mineral density.Published 2009. This article is a US Government work and is in the public domain in the USA.
Thyroid nodule with eggshell calcification and oncocytic thyroid cancer. - Medical science monitor : international medical journal of experimental and clinical research
To report an interesting case of Hurthle cell cancer of the thyroid with eggshell calcification, including ultra-sonographic, surgical, histological, and immuno-histochemical findings and discussion of diagnostic and therapeutic strategies.A 62 year old asymptomatic man with negative history of radiation, referred for evaluation of a thyroid nodule, had a 3-4 cm firm, mobile nodule in the left lobe of his thyroid. US of the thyroid revealed a normal right lobe and a large heterogeneous mass that was iso- and hyper-echoic, with peripheral halo and intra-nodular and peripheral coarse calcifications, measuring 2.8 x 3.0 cm, in the left lobe. US-guided FNA revealed a richly cellular specimen with numerous sheets of Hurthle cells with nuclear pleomorphism and intranuclear vacuoles. At macroscopic examination after thyroidectomy, an encapsulated tumor mass measuring 5.0 x 3.5 x 2.6 cm was found to have replaced the entire left lobe. The capsule was thick and hard, preventing the specimen from being cut, and requiring 3 days of pretreatment with a decalcifying agent before sections could be made. Microscopic examination revealed oncocytic or Hurthle cell carcinoma with pericapsular and vascular invasion. The patient received radioiodine ablation and was placed on suppressive doses of levothyroxine. At follow up, the thyroid ultrasound and scan remain negative with undetectable thyroglobulin. We could not find any reports of Hurthle cell thyroid cancer with such coarse or eggshell calcification.Egg shell calcification does not exclude the presence of camcer.
Metabolic syndrome and cancer. - Metabolic syndrome and related disorders
Since its first description by Reavan in 1988, accepted criteria for clinical identification of the components of metabolic syndrome have been promulgated by the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) and the World Health Organization (WHO) as well as the International Diabetes Federation (IDF), and the American Association of Clinical Endocrinologists (AACE). Insulin resistance is a common metabolic abnormality underlying type 2 diabetes mellitus and is also an independent risk factor for cardiovascular disease. Although ATP III identified cardiovascular disease (CVD) as the primary clinical outcome of the metabolic syndrome, we now have evidence that metabolic syndrome is associated with type 2 diabetes mellitus, polycystic ovarian disease, nonalcoholic fatty liver disease, and possibly some cancers. This review summarizes evidence in support of the relationship between metabolic syndrome and various cancers and possible underlying mechanisms and therapeutic interventions.
Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. - Medical science monitor : international medical journal of experimental and clinical research
Metabolic syndrome is associated with decreased physical activity and increased incidence of diabetes. Bone Mineral density (BMD) is positively associated with physical activity. Lower BMD is a risk factor for bone fractures. Whether subjects with metabolic syndrome alone show early signs of lower BMD and osteoporosis similar to those present in diabetic is not known.This cross-sectional study in male veterans examined the BMD in 3458 non-diabetic men and 735 men with type 2 diabetes. In addition, the BMD changes in non-diabetic men without any metabolic syndrome were compared with non-diabetic men with metabolic syndrome as established by the criteria of the Adult Treatment Panel III.BMD of hip was significantly lower and incidence of osteoporosis higher in diabetic subjects compared with age and body mass index (BMI) matched non-diabetic subjects. BMD of AP spine was significantly higher in diabetic subjects compared with non-diabetics but similar when subjects were matched for BMI. Men with metabolic syndrome alone had higher osteoporosis and lower BMD of hip compared with those without metabolic syndrome.The BMD of hip is lower in diabetics compared with age and BMI-matched non-diabetic men, and its level is similar in age and BMI-matched diabetics and non-diabetic men with metabolic syndrome. This suggests that both diabetes and metabolic syndrome are associated independently with higher osteoporosis and lower BMD of hip and are risk factors for increased incidence of hip fractures in men.
Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. - Cytokine
Our objective of this study is to investigate the relationship between plasma osteoprotegerin (OPG) levels in type 2 diabetes and its relationship with the insulin resistance, HbA(1c), CRP, and TNF-alpha levels.In a cross-sectional study, levels of OPG were determined in 50 subjects with type 2 diabetes and 59 control subjects without diabetes. The OPG levels between the groups were compared and their correlation with insulin resistance, glycemia and inflammatory markers CRP and TNF-alpha was determined.OPG levels were elevated in subjects with diabetes (6.8+/-0.27 pmol/l), compared to control subjects (5.7+/-0.26 pmol/l). OPG levels significantly correlate with insulin, insulin resistance, CRP, and TNF-alpha.OPG levels are significantly correlated with insulin resistance and may reflect the proinflammatory state in type 2 diabetes.

Map & Directions

Overton Brooks Va Medical Ctr Shreveport, LA 71101
View Directions In Google Maps

Nearby Doctors

1801 Fairfield Ave Suite 201
Shreveport, LA 71101
318 482-2810
1303 Line Ave Ste 400
Shreveport, LA 71101
318 212-2707
1 Saint Mary Pl
Shreveport, LA 71101
318 274-4658
501 E Stoner Avenue
Shreveport, LA 71101
318 218-8411
510 E Stoner Ave Primary Care (110)
Shreveport, LA 71101
318 218-8411
1801 Fairfield Ave Suite 401
Shreveport, LA 71101
318 248-8373
1006 Highland Ave
Shreveport, LA 71101
318 490-0882
510 E Stoner Ave
Shreveport, LA 71101
318 218-8411
1534 Elizabeth Ave
Shreveport, LA 71101
318 817-7980
416 Travis St Suite 1200
Shreveport, LA 71101
318 227-7464